A non-apoptotic type of controlled cell death is ferroptosis. It differs from other types of controlled cell death, like apoptosis and necroptosis. Large-scale lipid peroxidation, which is a hallmark of ferroptosis, can be prevented by lipophilic antioxidants or iron chelators. Ferroptosis inducers can be categorized into two groups based on their mechanisms: (1) inhibitors of cystine import via system xc (such as Erastin), which lead to the depletion of glutathione (GSH), and (2) covalent inhibitors of glutathione peroxidase 4 (GPX4), such as (1S, 3R)-RSL3.Both compound classes ultimately lead to a loss of GPX4 activity, which is followed by increased levels of lipid reactive oxygen species (ROS) and eventual cell death. GPX4 reduces lipid hydroperoxides using GSH as a co-substrate.
Iron and ROS are required for the regulated cell death (RCD) process known as ferroptosis. Misregulated ferroptosis has been linked to a number of physiological and pathological processes, such as T-cell immunity, drug-induced hepatotoxicity, hepatic and heart ischemia/reperfusion injury, neurotoxicity, and the death of cancer cells.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
![[2H3]-罗格列酮标准品](http://www.invivochem.com/upload/1124/V51332.png)
|
V51332 | Rosiglitazone-d3 (BRL-49653-d3) | 1132641-22-5 | deuterated form of Rosiglitazone |
|
V79509 | Anticancer agent 154 | Anticancer agent 154 (Compound 8h) increases levels of reactive oxygen species and causes mitochondrial damage. | |
|
V3193 | CA3 (CIL-56) | 300802-28-2 | CA3 (also known as CIL56) is a novel and potent inhibitor ofYAP1/Teadtranscriptional activity. |
|
V18692 | CP-24879 hydrochloride | 10141-51-2 | CP-24879 hydrochloride (CP24879; p-isopentoxyaniline)) is a novel and potent dual inhibitor of D5D/D6D (delta5 and/or the delta6) fatty acid desaturasewithantisteatotic and anti-inflammatory activity. |
|
V79163 | DL-alpha-Tocopherol-13C3 (DL-alpha-Tocopherol 13C3) | DL-alpha-Tocopherol-13C3 is a 13C (carbon 13)-labeled DL-alpha-Tocopherol. | |
|
V77077 | DL-Buthionine-(S,R)-sulfoximine hydrochloride (Buthionine sulfoximine hydrochloride; BSO hydrochloride) | DL-Buthionine-(S,R)-sulfoximine HCl (Buthionine sulfoximine HCl) is a potent inhibitor of glutamylcysteine synthetase biosynthesis. | |
|
V79369 | FA16 | 3037775-42-8 | FA16 is a specific, metabolically stable ferroptosis inducer (IC50=1.26 μM; HT1080 cells) and is an analogue of 2-(trifluoromethyl) benzimidazole. |
|
V79357 | Ferroptosis-IN-1 | Ferroptosis-IN-1 is a ferroptosis diterpenoid. | |
|
V79405 | Ferroptosis-IN-3 | Ferroptosis-IN-3 (Compound 25) is a ferroptosis inhibitor. | |
|
V76016 | Ferroptosis-IN-4 | 2798922-35-5 | Ferroptosis-IN-4 is a ferroptosis inhibitor (antagonist) with EC50 of 20 μM. |
|
V76015 | Ferroptosis-IN-5 | 2991058-60-5 | Ferroptosis-IN-5 (compound 9c) is a ferroptosis inhibitor (antagonist) with iron chelating and reactive oxygen species (ROS) scavenging activities. |
|
V2767 | FIN56 | 1083162-61-1 | FIN56 (FIN-56),a specific inducer of ferroptosis, causes the loss of GPX4 activity in cell lysates. |
|
V79011 | GPX4-IN-7 | GPX4-IN-7 (Compound 31), an indirubin analogue, is a ferroptosis inducer in colon cancer. | |
|
V79733 | HDAC-IN-48 | 3031411-05-6 | HDAC-IN-48 is a potent HDAC inhibitor and a cytotoxic hybrid molecule. |
|
V76017 | icFSP1 | 1115910-36-5 | icFSP1 is a potent inhibitor of ferroptosis suppressor protein-1 (FSP1). |
|
V39586 | iFSP1 | 150651-39-1 | iFSP1 is a novel and glutathione-independent inhibitor offerroptosis suppressor protein 1(FSP1) (AIFM2) with an EC50 of 103 nM. |
|
V76833 | L-Buthionine-(S,R)-sulfoximine hydrochloride (L-Buthionine sulfoximine hydrochloride; L-BSO hydrochloride) | L-Buthionine-(S,R)-sulfoximine HCl is a cell-permeable (penetrable), potent, fast-acting, orally bioactive, irreversible G-glutamate cysteine synthetase (γ- glutamylcysteine synthetase) inhibitor, which can reduce intracellular glutathione levels. | |
|
V80533 | Lapatinib-d7 dihydrochloride (GW572016-dd7 (dihydrochloride); GW2016-dd7 (dihydrochloride)) | Lapatinib-d7 (di-HCl) is the deuterated form of Lapatinib di-HCl. | |
|
V79062 | Lovastatin-d9 (Lovastatin d9) | Lovastatin-d9 is the deuterium labelled form of Lovastatin. | |
|
V50961 | MMRi-62 | 352693-80-2 | MDM4-degrader and ferroptosis/apoptosis inducer |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
